Catalyst
Slingshot members are tracking this event:
Celgene (CELG) expects topline data readout in mid-2018 for Phase 3 luspatercept study in patients at low risk Myelodysplastic syndromes (MDS)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CELG | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 09, 2018
Occurred Source:
http://ir.celgene.com/releasedetail.cfm?releaseid=1071730
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Topline Data, Luspatercept, Myelodysplastic Syndromes
